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Abstract  
 
Despite being a ubiquitous animal pain model, the natural TRPA1-agonist allyl-isothiocyanate 
(AITC, also known as “mustard oil”) has only been sparsely investigated as a potential human 
surrogate model of pain, sensitization, and neurogenic inflammation. Its dose-response as an 
algogenic, sensitizing irritant remains to be elucidated in human skin.  
Three concentrations of AITC (10%, 50%, 90%) and vehicl  (paraffin) were applied for 5 min to 
3x3 cm areas on the volar forearms in 14 healthy volunteers, and evoked pain intensity (visual 
analog scale 0-100 mm) and pain quality were assessed. In addition, a comprehensive battery of 
quantitative sensory tests was conducted including assessment of mechanical and thermal 
sensitivity. Neurogenic inflammation was quantified using Laser Imaging perfusion (FLPI). 
Erythema and hyperpigmentation were assessed before, immediately after, and ≈64 hours after 
AITC exposure.   
AITC induced significant dose-dependent, moderate-to-severe spontaneous burning pain, 
mechanical and heat hyperalgesia as well as dynamic me hanical allodynia (p <0.05). No 
significant differences in induced pain hypersensitivity were observed between the 50% and 90% 
AITC concentrations. Acute and prolonged inflammation was evoked by all concentrations and 
assessments by FLPI demonstrated a significant dose-dep ndent increase with a ceiling effect 
from 50% to 90%. 
Topical AITC application produces pain and somatosensory sensitization in a dose-dependent 
manner with optimal concentrations recommended to be >10% and ≤50%. The model is 
translatable to humans and could be useful in pharmacological proof-of-concept studies of 
TRPA1-antagonists, analgesics and anti-inflammatory compounds or for exploratory clinical 
purposes, e.g. loss- or gain-of-function in peripheral neuropathies. 
 
 
1. Introduction 
 
The natural transient receptor potential cation channel A1 (TRPA1)-agonist allyl-isothiocyanate 
(AITC), also known as “mustard oil”, has been used ubiquitously as an in vivo pain model in 
hundreds of preclinical studies [8,16,17,45,54]. It generates inflammation and spontaneous pain 
behavior as well as robust thermal and mechanical hyperalgesia [31,35,66]. Following cutaneous 
application, this symptomatology is evoked through activation of TRPA1-positive epidermal C-
nociceptors. Notably, several additional animal models beyond AITC application, rely partly or 
entirely on TRPA1 as their substrate, e.g. models using formalin and trans-cinnamaldehyde 
[21,54,82].  
 
The physiological role of TRPA1 in the sensory nervous system is not only restricted to 
chemonociception [39,47,53,60]; the channel has also been suggested to play important roles in 
mediating cold pain sensation [6,23,80], pruriception [28,46,84], the cough reflex [24,64] and to 
act as an immunological co-activator [15,69]. The TRPA1-channel is substantially co-expressed 
with transient receptor potential cation channel V1 (TRPV1) on peptidergic nociceptors [34] and 
these frequently act in conjunction to detect numerous environmental chemical irritants although 
AC
CE
PT
ED
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
3 
it is currently unclear to which extend they are functionally dependent on each other [22,70,79]. 
Recently, TRPA1 has been widely implicated in a number of painful and inflammatory conditions 
and is considered a promising potential target for he development of, amongst others, analgesic, 
antipruritic and anti-inflammatory pharmacotherapeutics [4,21,36,64]. For instance, the channel 
has been proposed to play a role in the pathoetiology of numerous disorders based on in vivo 
studies including neuropathic pain [9], migraine [11] and arthritis [29] and expression of the 
channel has been found upregulated in human tissues in conditions such as oral lichen planus 
[40], post-burn pruritus [85] and inflammatory bowel disorder [41] – conditions that are often 
associated with neuro-inflammation and pain. In line with these observations, a number of 
TRPA1-antagonists are currently being developed to target conditions such as neuropathic pain, 
irritable bowel diseases, inflammatory skin disorders and itch [4,12,21,36,64].  
 
Despite its very widespread usage as a model of TRPA1-induced pain in animals, the AITC-
model has not been extensively studied in humans [25,37,38,83]. The few previous studies 
applying topical AITC in humans predate the discovery of TRPA1 and mainly assessed certain 
aspects of the somatosensory aberrations or neuronal events induced by AITC [25,37,38,75,83]. 
Does-response features of this model have not previously been investigated. Given the difficulty 
and high failure-rate associated with turning preclini al findings on promising anti-nociceptive 
and anti-hyperalgesive compounds into feasible analgesics for human use [54], translatable 
mechanism-specific human surrogate models of pain, such as the AITC model, are warranted 
[5,63] and it is thus necessary to have dose-response information for the sensitization features of 
interest. Moreover, AITC might constitute a relevant receptor-specific pain probing modality, 
which could be applied to gain insights into pain mechanisms e.g. loss- or gain-of-function in 
patients with neuropathic pain [33,57].  
 
The aim of the present study was to assess the dose-response features of topical AITC 
provocations on evoked pain and pain-associated sensory aberrations. Beyond evaluating evoked 
pain intensity and quality, a comprehensive battery of quantitative sensory tests was conducted 
together with evaluation of neurogenic inflammatory responses. 
 
2. Methods 
 
2.1 Study design and subjects 
Fourteen healthy subjects including 10 males and 4 females, aged 19–28 years (mean (±SD): 23.5 
± 3.1 years) were recruited. The subjects were pain-free, without previous known neurological, 
dermatological, allergic or musculoskeletal disorders. All subjects signed a statement of informed 
consent in accordance with the Helsinki Declaration, before participation. The regional ethics 
committee approved the experiment (study no. N-20160 6 ). Prior to the onset of the experiment 
all subjects were instructed verbally and in writing that all experimental procedures could be 
stopped immediately if the pain or discomfort became intolerable, as well as that they are free to 
withdraw from the study at any point without incurring consequences. The study was carried out 
in a double-blinded manner with balanced randomization of both the order of AITC applications, 
the application sites within each volar forearm (proximal vs. distal locations) and dominant versus 
non-dominant arm. Randomization of right vs. left was done under the condition that arms always 
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shifted between the applied solutions. Both the investigator and the subjects were blinded to the 
AITC concentration/vehicle being applied. Every time a substance was administered, a bottle of 
pure 99% allyl-isothiocyanate was opened in the labor tory. This was done to create a powerful 
ambient smell of mustard oil, in order to inhibit the investigator and participants’ ability to 
identify the order of solutions investigated, by olfaction. A similar procedure has previously been 
utilized in studies using highly odorous compounds to avoid unmasking of subjects and 
investigator [26,58,61]. The study was conducted as a single session lasting approximately 2.25-
2.75 hours, wherein the participants were exposed to all four solutions, interspersed with short 
breaks following each panel of sensory testing (Fig. 1). The ambient temperature was kept at ≈21-
22 °C in all sessions. 
 
2.2. Application of allyl-isothiocyanate 
AITC (≥99%) was obtained from Sigma Aldrich (Broendby, Denmark) and dissolved in pure 
paraffin (European Pharmacopoeia, Løve-Apoteket, Aalborg, Denmark) at concentrations of 
10%, 50% and 90% (all v/v concentrations). These concentrations were determined by 
precedence in the literature showing that 100% AITC evokes a considerable pain and allodynia 
[38] and by initial pilot studies showing that much lower concentrations were likely sufficient to 
induce similar pain, hyperalgesia, and prominent neurogenic flare. Paraffin was chosen as the 
vehicle because of 1) its previous application for the purpose of applying AITC, 2) its lack of 
toxicity, 3) its lack of somatosensory effects. A one mL aliquot of each concentration was 
dispensed into a 3 × 3 cm cotton pad and placed in a custom-made polypropylene chamber (3 x 3 
x 0.18 cm) (Aalborg University, Aalborg, Denmark). The chamber containing the cotton pad was 
then fixed to the pre-marked skin areas on the volar f rearms using medical tape (BSN, Hamburg, 
Germany). With two pre-marked 3x3 cm areas on each volar forearm, the same skin areas were 
never re-used. The two areas were 6 cm apart (each 3 cm away form the midpoint between the 
elbow and wrist creases) to assure non-overlapping flare quantification. The application 
configuration was applied for 5 min before being carefully removed after which residual 
AITC/vehicle solution was gently washed of the skin. The AITC was deliberately removed before 
proceeding, because initial pilot experiments demonstrated that if the skin area is not cleaned 
thoroughly, the induced pain would only subside slowly and increased hyperpigmentation would 
occur.  
 
2.3. Pain assessment  
For each concentration applied, the participants were instructed to rate the pain intensity for 5 min 
on a 100 mm visual analog scale (VAS) ranging from “no pain” = 0, to “worst imaginable pain” 
= 100. To this end, a digital VAS using eVAS software (Aalborg University, Denmark) installed 
on a 10.1” Samsung tablet computer (Samsung Electroni s, Seoul, Korea) was used and the pain 
intensity was sampled at 0.2 Hz. Subjects expressed th ir pain quality by choosing word 
descriptors from a validated brief descriptive Danish version of the McGill Pain Questionnaire 
(MPQ). A list of the applied sensory descriptors can be found in [62]. Pain quality was 
determined at 4 minutes post AITC application corresponding to a time point where moderate to 
intense pain was perceived in the majority of subjects. After the pain assessment, Full-Field Laser 
Perfusion Imaging (FLPI) was conducted and the subjects were asked to report when the pain 
subsided before proceeding with sensory testing.  
AC
CE
PT
ED
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
5 
 
2.4. Quantitative sensory testing (QST) 
The QST battery of the present study was partly derived from the guidelines of the German 
Research Network on Neuropathic Pain (DFNS) [68]. The verbal instructions (in Danish) for 
participants from the DFNS protocol were derived from the supplementary materials of Olsen et 
al. (2014) [61]. The terminology used to describe the induced sensory derangement are defined 
by Sandkühler (2009) [71]. 
 
2.4.1 Thermal detection and pain thresholds: Tests for cold detection threshold (CDT), warmth 
detection threshold (WDT), cold pain threshold (CPT), and heat pain threshold (HPT) were 
performed using a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 × 3 cm 
advanced thermal stimulator probe with a baseline temperature of 32°C.  Ramping stimuli of 1 
°C/s were delivered in each application area following AITC and when the subjects identified the 
associated threshold (first perception of cold or wa mth and first perception of cold or heat pain) 
they pressed a button that returned the temperature of the probe to the baseline at a rate of 5 °C/s. 
The results were calculated as the arithmetic mean of the thresholds from three repeated ramps.  
2.4.2 Mechanical pain thresholds and sensitivity: To evaluate the mechanical pain threshold 
(MPT), a set of 7 weight-calibrated pinprick stimulators (MRC Systems, Germany) with weights 
of 8, 16, 32, 64, 128, 256, and 512 mN was applied. During five ascending/descending series of 
stimuli, the subjects were instructed to report when a perception of ‘sharpness’ or ‘pricking pain’ 
was first sensed. The final MPT was calculated as the geometric mean of the values obtained in 
the five series of stimuli. The mechanical pain sensitivity (MPS) was assessed to detect pinprick 
hyperalgesia to suprathreshold stimulation. The sevn pinprick stimuli were applied in ascending 
order three times and for each stimulus the subjects were instructed to rate the pain intensity on a 
numerical rating scale (NRS) from 0–10 (0 = no pain, 10 = worst imaginable pain). Subjects 
were explicitly instructed to use decimals as suitable. The final MPS was calculated as the 
arithmetic mean of three consecutive series of the seven stimuli. The wind-up ratio (WUR) was 
assessed using the pinprick stimulator one intensity above the average MPT. The subjects were 
asked to rate their pain intensity following a single stimulus and thereafter of a subsequent series 
of 10 consecutive stimuli (1 stimuli/s) applied within the area of substance application. This 
procedure was repeated three times.  
2.4.3 Allodynia: Dynamic mechanical allodynia (ALL) was assessed using a normally innocuous 
stimuli moving, i.e. a standardized sensory brush (SENSElab 05-brush, Somedic, Hörby, 
Sweden) exerting a force of 200–400 mN. It was always confirmed that subject perceived the 
stimulation as non-painful in an area at least 10 cm away from the relevant AITC-pretreated skin. 
Subsequently, the tactile stimulus was applied three times with a single stroke of approximately 3 
cm in length within the AITC-pretreated skin. The subjects were instructed to rate whether pain 
occurred and if so to rate the pain intensity on the same numerical rating scale used for MPS.  
 
2.5 Neurogenic inflammatory response and pigmentation  
FLPI was used to assess the superficial blood perfusion immediately after removing the 
AITC/paraffin chamber. The measurements were conducte  using a MoorFLPI-1 (Moor 
Instruments Ltd, Axminster, UK). The perfusion assessment was conducted with a 35-cm 
distance between the camera and the application area with an exposure time of 8.3 ms and 160 
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units of gain. The FLPI data were analyzed using MoorFLPI Review V4.0 proprietary software. 
The induced increases in average and peak superficial blood perfusion within the 3 x 3 cm 
application areas were used as proxies for primary neurogenic inflammation intensity. Moreover, 
the axon-reflex flare size was calculated as the area associated with the AITC provocation 
exhibiting a ≥30% increase compared to the surrounding perfusion background. The size was 
quantified in cm2
 
by relative comparison to the known size of the 3 x 3 cm pre-marked 
application area. The 9 cm2 in which AITC was applied was then subtracted from the score thus 
giving rise to an estimate of the size of the secondary neurogenic inflammation or the “reflex 
response”. This method has previously been applied to quantify the neurogenic inflammatory 
response to various chemical irritants [1,2,61]. The erythema (redness) and skin pigmentation 
were measured with a spectrometer designed for cutaneous use (ColorMeter, DSM II, Cortex 
Technology, Hadsund, Denmark) as previously utilized [56] . The device provides a read-out of 
erythema and pigmentation based on the light absorption characteristics of skin for wavelength 
corresponding to hemoglobin (erythema) and melanin (pigmentation). Erythema and 
pigmentation data was recorded before, immediately after AITC removal and ≈64 hours (48-96 
hours range) after the experimental session.  
 
2.6 Statistics  
Sample size calculation was conducted based on previously obtained data applying similar pain 
models [61] and using the approached outlined  for cr ssover designs [56]. The obtained data are 
presented as arithmetic or geometric means (non-linear stimulus modes) ± the standard error of 
the mean (SEM), unless otherwise stated. Data from all assessments were tested for normality 
using visual inspection of Q-Q plots and the Shapiro-Wilk normality test when necessary. 
Average and peak pain intensity induced by the AITC were calculated and compared from VAS-
recordings while categorical variables are shown as % of distribution without further hypothesis 
testing. The primary analyses were conducted using repeated measures analyses of variations 
(RM-ANOVAs) with the factor: concentration (four levels) using Fisher’s least significant 
difference (LSD) test post hoc test in a step-wise manner. For erythema and pigmentation data, an 
additional level of time was added to the RM-ANOVA and values were always normalized to the 
values obtained from the vehicle area to account for day-to-day variability. While all statistical 
tests were conducted using raw data, the temporal profiles of evoked pain (Fig. 2A) were 
downscaled to one data point per 0.5 min by calculating the average of six 0.2 Hz ratings. Z-
scores were calculated to provide a relativized overview of induced sensory sensitization using 
the formula [Z = (χ-µ)/σ] where “χ” is the average value following AITC, “µ” is the average value 
in the vehicle condition and “σ” is the combined standard deviation for the parameter across the 
four solutions. Data handling and calculation of descriptive statistics were carried out in Excel, 
while statistical comparisons were performed in SPS (Both software packages: Windows, 
Redmond, WA, USA) and graph plotting was conducted in GraphPad Prism. A p-value of ≤ 0.05 
was considered significant. 
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3. Results 
 
All enrolled participants finished the study and topical administration of AITC was well tolerated 
and did not produce any unexpected side effects (e.g. local edema, blistering, desquamation or 
systemic reactions). No subjects withdrew from the study nor terminated any of the experimental 
procedures. The spontaneous pain evoked by AITC generally resolved quickly after removing 
residual solution. AITC-evoked pain subsided quickly after removing residual solution and all 
subjects confirmed that no pain remained before the sensory testing was started. Due to technical 
issues, the erythema and pigmentation data is missing for one subject (excluded from relevant 
analyses, n = 13). The study was designed to assess th  dose-response function of AITC, not to 
detect any potential sex differences in AITC-induced r sponses and hence no sub-analysis on data 
was conducted for this purpose. No significant differences were observed related to order of 
AITC administration or arm dominancy.  
 
3.1. Evoked pain intensity and quality  
The most frequently reported descriptors of the evok d pain quality were: “warm/burning” (10% 
n = 5/14, 50% = 10/14, 90% = 10/14), “searing” (10% = 8/14, 50%= 9/14, 90% = 7/14) and 
pricking/stinging (10% = 7/14, 50% = 3/14, 90% = 5/14). Four subjects described the vehicle as 
inducing a mild “cold/freezing” sensation. The mean pain intensity was a dose-response-
dependent for both mean ratings and peak pain (F(3,39) = 29.9, p < 0.001), see Fig. 2A and 2B. 
Post hoc testing revealed that all AITC conditions induced more intense pain than the vehicle (p < 
0.01) and that both 50% and 90% AITC induced higher pain intensity than 10% AITC (p < 0.01). 
This was true for both mean and peak pain ratings. No significant difference was found between 
50% and 90% AITC. Peak pain intensity reached to 41.43 ± 6.17 for 10% AITC, 56.9 ± 7.77 for 
50% AITC, and 59.9 ± 7.46 for 90% AITC. Negligible pain was reported following the vehicle 
application in two subjects who rated it on the VAS (both < 5 out of 100).  
 
3.2. Thermal sensory sensitivity  
Thermal cold as well as warmth detection thresholds remained unchanged following application 
of AITC regardless of the concentration applied (F(3,39) = 0.35, p > 0.7 and (F(3,39) = 2.83, p > 
0.05) indicating that neither thermal hypo- nor hyperesthesia was induced by AITC (Fig. 2C). 
The cold pain threshold was, however, altered by AITC (F(3,39) = 3.93, p < 0.05), with post hoc 
tests revealing that cold hypoalgesia was only significa tly elicited in the 90% AITC condition (p 
< 0.05) compared with vehicle. Conversely, HPT decreased significantly and in a dose-dependent 
manner (F(3,39) = 86.0, p < 0.001). While 10% was insufficient to produce heat hyperalgesia, 
both 50% and 90% evoked substantial decrease in HPT from 40.9 ± 0.92 °C in the vehicle 
condition to 37.1 ± 0.47 °C following 50% AITC and 36.8 ± 0.50 °C following 90% AITC (Fig. 
2D). Heat pain thresholds were also significantly lower in the 50% and 90% AITC conditions 
compared to the 10% condition, but no difference was found between 50 and 90% AITC 
concentrations.  
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3.3. Mechanical hyperalgesia and allodynia 
AITC induced dose-dependent mechanical hyperalgesia as evident by increased MPS, including 
mechanical stimuli in the suprathreshold range, was significantly increased for all AITC 
concentrations but no clear dose-dependency was evident n the response (Fig. 3A). However, 
trends toward higher MPS following 50% and 90% AITC compared to the 10% AITC were 
evident (p = 0.051 and 0.099, respectively). MPT (F(3,39) = 8.41, p < 0.01) decreased following 
50% and 90% AITC administration with approximately ⅔ (Fig. 3B). While all AITC 
concentrations evoked significant decreases in MPT with respect to vehicle, 50% and 90% AITC 
yielded significantly further decreases compared with 10% (p < 0.05). The wind-up-ratio (WUR) 
to pinprick pain stimuli was unaffected by AITC (F(3,39) = 1.34, p > 0.05, data not shown). 
AITC induced significant dose-dependent allodynia to brush (F(3,39) = 15.8, p < 0.001). For 10% 
AITC 9/14 subject reported allodynia, for 50% 11/14 reported it and for 90% 13/14 reported it. 
Again, all AITC concentrations induced significant allodynia compared to vehicle, but 50% and 
90% AITC induced more pronounced allodynia than 10%, while no differences was present 
between 50% and 90% AITC. The brush-evoked allodynia was always perceived as non-painful 
in normal intact skin on the volar forearm treated with vehicle. Notably, most subjects 
spontaneously reported pain associated with gentle wiping of the skin immediately next to the 
application areas treated with 50% and 90% AITC, when residual solution was removed from the 
application site. This indicates that while not quantified in the present study, secondary allodynia 
to innocuous touch was evoked. For a comparative overview of the somatosensory aberrations 
induced by the AITC (see Fig. 4).  
 
3.4. Neurogenic inflammatory response  
All concentrations of AITC induced robust neurogenic i flammation for mean (F(3,39) = 38.6, p 
< 0.001) and peak values (F(3,39) = 34.1, p < 0.001)  Clear dose-response relationships were 
evident for these parameters although no significant differences were detected between 50% and 
90% AITC for both mean and peak perfusion (Fig. 5A and B). Notably, all AITC concentrations 
also induced a secondary inflammatory response known as “axon-reflex-flare” (F(3,39) = 56.8, p 
< 0.001), The size of this response was also dose-dep ndent with the 90% AITC concentration 
inducing a larger axon-reflex-flare than the 10% concentration (p > 0.05), with 17.0 ± 1.29 cm vs. 
13.0 ± 1.87 cm, respectively (Fig. 5C). For primary e thema measured by spectroscopy there 
was only an effect of time (F(2,24) = 131.3, p <0.001) but not for concentration (F(2,24) = 2.56, p 
= 0.099) nor was there an effect of c ncentration x time interaction. Post hoc testing showed that 
erythema increased following all AITC concentrations and then decreased considerably when 
measured approximately 64 hours after the initial AITC exposures, although the erythema still 
remained detectable (p < 0.01). At 64 hours, there was generally no visually perceptible 
inflammation in the AITC-treated area (Fig. 5D). For pigmentation no significant changes 
occurred at group level for neither time (F(2,24) = 0.86, p = 0.44) nor concentration (F(2,24) = 
0.19, p = 0.44). However, slight but visually discernable hyperpigmentation occurred in 6/14 
subjects following 50% AITC and 8/14 following 90%, indicating poor resolution for colorimetry 
of pigmentation (Fig. 5E). This hyperpigmentation generally resolved within 1-2 weeks after the 
study start.  
 
AC
CE
PT
ED
Copyright  2017 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
9 
 
4. Discussion 
 
The present study showed that 5 min topical application of AITC (mustard oil) produces pain and 
somatosensory sensitization in a dose-dependent manner i  healthy human skin. The model 
evoked robust mechanical hyperalgesia, allodynia, heat hyperalgesia, and neurogenic 
inflammation. Notably, no significant additional sen itization and pain was achieved when using 
90% compared with 50% AITC, indicating a ceiling effect. Based on the present study, AITC 
concentrations of >10% and ≤50% are likely ideal for elicitation of robust sensory pain 
symptomatology, while minimizing unnecessary exposure. 
 
4.1 Evoked pain intensity and quality  
AITC induced dose-dependent, predominantly burning pain, conceivably corresponding to its 
activation of TRPA1-expressing C-nociceptors in theepidermis. This is well aligned with a 
previous paper by Koltzenburg et al. (1992) reporting very similar finding related to 
chemogenically-induced pain and pain quality for 100% (pure) AITC applied to a smaller area 
(2x2 cm) for 5 minutes. The predominant burning sensation is also in line with additional 
previous evidence [37,49]. Notably, the relatively rapid onset (1-3 min) of pain following topical 
administration has previously been observed [38] corresponding to the temporal profile observed 
in the present study. The AITC model works noticeably faster than topical capsaicin (a TRPV1-
agonist), a feature likely related to the fact that it is a smaller and more soluble molecule. 
Notably, the topical capsaicin-model has been extensiv ly used as a TRPV1-pain and 
inflammation specific model in early pharmaceutical proof-of-concept studies for drugs 
developed for various clinical conditions involving TRPA1 [64].  
  
4.2. Thermal sensory sensitivity  
AITC did not induce changes in the detection of innocuous cold and warmth, indicating that 
afferent units conveying these sensations, within te detection threshold range, are likely TRPA1-
negative. This corresponds to the prevailing notion of these fibers being myelinated cold Aδ-
fibers and warmth-selective C-fibers, respectively [14]. While the effect of AITC-induced 
TRPA1-activation on thermal detection thresholds have not previously been assessed, the present 
results do correspond to findings stemming from therans-cinnamaldehyde model, which 
similarly have no, or very limited effects on thermal detection thresholds [2,58,61]. Oppositely, 
CPT was decreased by the 90% AITC concentration sigify ng cold hypoalgesia and a similar, 
but insignificant trend was observed for 50%. This observation has previously been made for 
irritants inducing burning pain, for instance capsaicin and trans-cinnamaldehyde, and it has been 
suggested that this could be a consequence of the pleasantness or relieve associated with cold 
counter-stimuli on the affected skin. It is paradoxical, that both TRPA1-agonists; trans-
cinnamaldehyde and here AITC induce cold hypoalgesia and burning pain [58,67], given that 
TRPA1 has previously been implicated in cold pain sensation [19,32,51]. Cold pain is 
hypothesized to rely on a common nociceptive pathway for both nociceptive heat and cold along 
with simultaneous activation of innocuous cold Aδ-fibers. It has been suggested that TRPA1+-
afferents may mediate the burning component of noxious cold [18,58]. However, recent evidence 
indicates that TRPA1 is - by no means - selective to cold pain sensation [24,28,46,64,84] and that 
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the channel acts more as a general transducer and amplifier to certain noxious and pruritic stimuli 
[35]. Lastly, the evidence implicating TRPA1 in cold pain sensation is almost entirely derived 
from rodent studies and since peptidergic nociceptors in humans and rodents do exhibit notable 
dissimilarities, preclinical findings are not necessarily fully transferable [74]. Dose-dependent 
heat hyperalgesia, as evident from increased HPT, was provoked by AITC. Notably, both 50% 
and 90% AITC reduced the HPT to ≈ 37°C, i.e. approximately 2.5°C higher than HDT in the 
vehicle-treated skin. Heat hyperalgesia is conceivably evoked by primary sensitization of fibers 
responsible for conveying heat pain around the painthreshold territory, i.e. PmC- and Aδ-fibers 
[44,52]. Following TRPA1-activation by AITC these units respond at temperatures normally 
insufficient in evoking action potential and perhaps even at temperatures below that of the skinin 
situ. Given the estimated 65% co-expression of TRPA1/TRPV1 on peptidergic nociceptive fibers 
in rats [34], TRPA1-induced heat hyperalgesia, and perhaps cold hypoalgesia, is likely produced 
through same subpopulation of fibers that mediate these features in the capsaicin-model [20].  
 
4.3. Mechanical hyperalgesia and dynamic allodynia 
AITC induced dose-dependent decreases in MPT and corresponding increases in pain in response 
to mechanical supra-threshold pain stimuli (increased MPS), although no differences were present 
between the three AITC concentrations for the latter outcome parameter, even when comparisons 
were conducted with the LSD-test. Prolonged mechanical hyperalgesia has previously been 
described following a 5-min application of 100% AITC; however, in that study the secondary 
hyperalgesic area was mapped with a single 23g von Frey filament [38], contrasting the present 
quantification of primary hyperalgesic severity. Normal perception of pinprick pain is thought to 
primarily reflect type-1 Aδ-, and to a lesser extent, PmC-fiber input [48,78]. The primary 
hyperalgesia to pinprick stimuli observed in the present study likely reflects either primary 
sensitization of the aforementioned mechanoreceptiv units, and/or, perhaps more likely, 
sensitization occurring at the level of the spinal dorsal horn (central sensitization) [43]. Strikingly, 
a previous study has found that primary mechanical hyperalgesia induced by AITC persists 
during an A-fiber block, while a microneurography study has found that PmC-fibers were not 
sensitized following AITC application [38,75]. Mechanistically, the aforementioned sensitization 
would likely be evoked by activation of TRPA1-positive nociceptive peripheral afferent C-fibers 
[81] and subsequent effects on the second order nociceptive neurons in the dorsal horn [77]. 
These central neurons, in turn, receive convergent input from Aδ-nociceptors thus mediating an 
increased sense of mechanically evoked pricking pain (p nprick hyperalgesia) [42,77].This 
explanatory model of centrally mediated sensitization could also explain the pronounced, dose-
dependent AITC-induced elicitation of allodynia, which has also previously been observed lasting 
for at least 30 min post 5-min application of 100% AITC [38]. For allodynia, thickly myelinated 
low-threshold primary Aβ-afferents, rather than Aδ-fibers, normally mediating the sense of light 
touch, would converge onto the nociceptive dorsal horn neurons following the preceding AITC-
induced nociceptor barrage and produce the sensatio of brush-evoked pain [42,43,81]. This 
explanation is well aligned with the fact that a previous paper on AITC-induced hyperalgesia in 
humans reported significant secondary hyperalgesia (an aspect of sensitization not quantified in 
the present study), which is recognized to be a centrally mediated phenomenon affecting Aδ- 
(pinprick hyperalgesia) and Aβ-fibers (stroke-evoked allodynia). The wind-up-ratio for pinprick 
stimuli was unaffected by the AITC-provocations, which is in line with findings in capsaicin-
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induced hyperalgesic skin [50]. Pinprick hyperalgesia and the itch-related phenomena of 
hyperknesis and alloknesis, but not dynamic mechanial allodynia, have previously been reported 
following use of trans-cinnamaldehyde in humans [2,58,61], but in the present study only one 
subject reported a sensation of itch, conceivably due to the high levels of pain. Lastly, both 
dynamic mechanical allodynia and hyperalgesia are very well studied characteristics of the 
capsaicin model, which at least in part, activates a ubpopulation of nociceptive fibers co-
expressing TRPA1, and thus also recruited by AITC administration.   
4.4. Neurogenic inflammatory response 
It is suggested that the primary cause of the herein observed acute inflammation is predominantly 
neurogenic in origin due to three observations; 1) the secondary flare extended several 
centimeters away from the application area, 2) the flar  developed within minutes, 3) there was 
no sign of exudation (lack of wheal reactions) indicating that mast cell degranulation did not 
occur. The neurogenic inflammatory response is thoug t to primarily represent an efferent 
function of CMi-fibers [13,73]. With their large terminal aborizations and capacity to release e.g. 
the vasodilatory calcitonin-gene related peptide (CGRP), this subpopulation of afferent fibers can 
elicit neurogenic flare significantly beyond the are  where an irritant substance is applied 
[72,73,76]. Animal studies have shown that capsaicin-induced desensitization only inhibits acute, 
but not prolonged TRPA1-mediated inflammation and that anti-histamines has no anti-
inflammatory effect [7,30], while a human micro-neurography study has shown that the vast 
majority CMi-fibers are TRPV1-positive. Taken togeth r this may suggest that AITC produces 
inflammation through parallel neurogenic and immunological mechanisms; the initial 
inflammatory response being predominantly neurogenic through CMi-activation and the 
prolonged primary inflammation measured by spectrometry being primarily immune-driven. This 
further raises the question of to which extent TRPA1 is an independent nociceptive transducer in 
human skin (see section 4.4). No differences were obs rved on primary neurogenic flare or axon-
reflex-flare between 50% and 90% AITC, despite assessm nt with the LSD-test, likely indicative 
of a ceiling effect of either CGRP-release or vascular responsiveness to said neuropeptide or other 
vasoactive neuropeptides. A number of previous human studies using the TRPA1-agonist trans-
cinnamaldehyde have found a similar neurogenic flare pattern [58,61], suggesting that TRPA1 is 
expressed on a substantial proportion of CMi-fibers.  
4.5 TRPA1 as independent nociceptive transducer 
TRPA1 has been proposed to play a detrimental role in the pathoetiology of numerous disorders 
including neuropathic pain [9], chronic inflammatory skin diseases [59], irritable bowel disorders 
[41], migraine [11] and arthritis [29]. Notably, aberrant TRPV1-signalling, has also been 
suggested to be involved in many of these conditions a d there is evidence of structural and 
functional TRPA1/TRPV1 co-localization. However, while TRPA1 is certainly a TRPV1 
independent molecular nociceptive/chemoreceptive transducer, it is unclear whether there is a 
phenotypically significant subpopulation of afferent fibers that are TRPA1-expressing, but 
TRPV1-negative. A recent study showed that TRPA1-induced hyperalgesia relies entirely on 
TPRV1-expression [22], contradicting the conventional otion of functional independence 
[10,31]. As prior studies have almost exclusively been conducted in rodents, it would be relevant 
to assess whether TRPA1-induced pain and inflammation is inducible in human skin where 
TRPV1-positive nociceptors have been defunctionalized, e.g. by pre-application of high-
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concentration of capsaicin [3,27]. Using such defunctio alization of TRPV1-fibers in humans, it 
has recently been shown that a PAR2-mediated itch provocation, principally relying on co-
activation of TRPA1, is abolished when TRPV1-positive fibers have been ablated by prolong 8% 
capsaicin application [3]. This seems to indicate that at least the entire subpopulation of 
pruriceptive nociceptors characterized by PAR2/TRPA1-expression is also TRPV1-positive. In 
most aspects the observed pain response for AITC is similar to that known from topical capsaicin 
application [33,38,61]. However, likely associated with differences in skin penetration rates of 
these two chemical substances, AITC evokes pain and hyperalgesia more rapidly than capsaicin. 
Several limitations adhere to the results of the present study: 1) While steps were taken to assure 
blinding of subjects and the investigator, it was difficult to avoid unmasking of the vehicle 
condition given that no visible flare or no pain was present as opposed to the AITC conditions. 2) 
Although dose-response features were assessed in participants of both sexes, the study was not 
designed to detect potential sex differences, which are well established to exist in several 
experimental models and clinical pain conditions [55,6 ]. Future studies on TRPA1-induced pain 
and sensitization should address this key issue for this particular type of pain provocation. 3) 
While sensory testing was nominally conducted after the spontaneously evoked pain had 
subsided, it cannot be excluded that low-intensity discharges within the area continued and/or that 
pain sensitization could have been rekindled or maintained by the somatosensory testing on the 
treated skin. However, in order to minimize this possibility, the assessment of heat pain 
thresholds was conducted at the very end of each assessment panel for each applied solution. 
 
 
5. Conclusion 
The present study shows that topical AITC (mustard oil) is an effective, safe and easily 
applicable, human surrogate model of TRPA1-evoked pain, hyperalgesia, and neurogenic 
inflammation. For both evoked pain and most somatosensory sensitization parameters the model 
produces dose-dependent responses, with no significant additional effects beyond a concentration 
of 50%. To minimize risks and irritant exposure, future studies should therefore use AITC 
concentrations >10% to ≤50%. The model is suitable for experimental pain studies in healthy 
controls or patients with pain profiling and could be particularly useful in pharmacological proof-
of-concept studies of TRPA1-antagonists, analgesics and anti-inflammatory drugs.  
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Figure legends 
 
Figure 1. Flowchart of study procedures. For each of the four substance applications the 
assessments depicted above were conducted. AITC = allyl-isothiocyanate, ALL = allodynia; CDT 
= cold detection threshold; CPT = cold pain threshold; FLPI = full-field laser perfusion imaging; 
MPT = mechanical pain threshold; MPS = mechanical pain sensitivity; NRS = numerical rating 
scale; HPT = heat pain threshold; VAS = visual analog scale; WDT = warmth detection 
threshold; WUR = wind-up ratio. Notice that the order of AITC/vehicle application was 
randomized.  
 
Figure 2. Evoked pain and thermal sensitivity following application of AITC and vehicle. A) 
Evoked pain. B) Individual peak pain intensity. C) Thermal cold and warmth detection 
thresholds. D) Thermal cold and heat pain thresholds. Notice that B, C and D share the legend of 
subfigure D. Significance indicators: (*/#) = p < 0.05, (**/##) = p < 0.01, (***/###) = p < 0.001 # 
denotes that relevant AITC-applications were signifcantly different from the vehicle at the lowest 
observed p-value. AITC = allyl-isothiocyanate; CDT = cold detection threshold; CPT = cold pain 
threshold; HPT = heat pain threshold; VAS = visual analog scale; WDT = warmth detection 
threshold.  
 
Figure 3. Mechanical hyperalgesia and allodynia following AITC and vehicle. A) Mechanical 
pain sensitivity. B) Mechanical pain threshold. C) Dynamic mechanical allodynia. Notice that B 
and C share legends. Significance indicators: (*/#) = p < 0.05, (**/##) = p < 0.01, # denotes that 
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relevant AITC-applications were significantly different from the vehicle at the lowest observed p-
value. AITC = allyl-isothiocyanate; mN = miliNewton; NRS = numeric rating scale. 
 
Figure 4. Z-score plot of AITC-evoked sensitization. Z-transformed sensory changes evoked 
by AITC relative to the vehicle condition for thermal and mechanical assessments. AITC = allyl-
isothiocyanate, ALL = allodynia; CDT = cold detection threshold; CPT = cold pain threshold; 
FLPI = full-field laser perfusion imaging; MPT = mechanical pain threshold; MPS = mechanical 
pain sensitivity; NRS = numerical rating scale; HPT = heat pain threshold; VAS = visual analog 
scale; WDT = warmth detection threshold. 
 
Figure 5. Neurogenic inflammation, axon-reflex-flare, erythema and pigmentation following 
AITC and vehicle. A) Representative FLPI images of AITC-evoked neurogenic inflammation. 
B) Neurogenic inflammatory response as mean and peakvalues within the application area. C)
Area of axon-reflex-flare. D) Erythema before, immediately after and 64 hours after AITC. E) 
Pigmentation before, immediately after and 64 hours after AITC. Notice that B and C as well as 
D and E share legends. Significance indicators: (*/#) = p < 0.05, (**/##) = p < 0.01, (***/###) = p < 
0.001, # denotes that relevant AITC-applications were signif cantly different from the vehicle at 
the lowest observed p-value. AITC = allyl-isothiocyanate; arb. = arbitrary; cm = centimeter.  
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